Skip to main content
    I

    Ideaya Biosciences Inc (IDYA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $27.40
    -2.96 (-9.75%)

    Market Cap: $2.94B

    Last updated: Nov 17, 2026 at 4:33 PM ET

    Ideaya Biosciences Inc (IDYA) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Ideaya Biosciences (IDYA) has a market cap of $2.94B and an enterprise value of $2.67B. It kept -1149.62% of revenue as net income over the last 12 months. Revenue fell 82.99% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 8.91% below the market cap, as cash exceeds debt.

    Market Cap$2.94B
    Enterprise Value$2.67B
    Latest price (Nov 17, 2026)$27.40

    Key Dates

    The next earnings report is expected on Feb 15, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 15, 2027 (expected)
    Last Earnings DateNov 3, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 11.82% in the quarter ended Sep 30, 2026 and grew 9.29% a year over 2 years.

    Shares Outstanding102.94M
    Shares Change (YoY)+16.29%
    Shares Change (QoQ)+11.82%
    Share Count Growth (2Y CAGR)+9.29%

    Valuation Ratios

    Sales and book value multiples are 77.2x and 2.6x. Its year-end P/S ranged from 14.0x to 320.7x from 2020 to 2025.

    P/S Ratio77.2x
    Forward P/S69.2x
    P/B Ratio2.6x

    Valuation history and multiples

    Price Statistics

    The stock is down 14.75% over 52 weeks and trades 21.83% below its 50-day average.

    Beta (1Y)1.06
    52-Week Change-14.75%
    1-Month Change-18.96%
    3-Month Change-29.51%
    6-Month Change-3.25%
    5-Year Change+49.07%
    Total Return (1Y)-14.75%
    Total Return (3Y CAGR)-3.37%
    Total Return (5Y CAGR)+3.17%
    Return vs SPY (1Y)-30.28%
    Max Drawdown (1Y)-35.50%
    Max Drawdown (3Y)-69.23%
    Sharpe Ratio (1Y)-0.45
    Correlation with SPY (1Y)0.32
    50-Day Average$35.05
    200-Day Average$33.81
    52-Week Range$26.81 to $42.68
    RSI (14 Days)29.0
    Average Volume (20 Days)1.11M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 9.04x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio9.04x
    Quick Ratio9.04x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -38.46% over the last 12 months, against a 5-year average of -17.70%.

    Return on Equity (ROE)-38.46%
    Return on Assets (ROA)-34.54%
    ROE (5Y Average)-17.70%
    ROA (5Y Average)-16.05%
    ROIC (5Y Average)-8.78%
    Asset Turnover0.03x

    Scores

    IDYA has an Altman Z-Score of 12.02, in the safe zone above 2.99, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score12.02
    Altman Z ZoneSafe
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $36.53M over the last 12 months.

    Revenue$36.53M
    Revenue Growth (YoY)-82.99%
    Gross Profit$36.53M
    Operating Income-$463.04M
    Pretax Income-$407.75M
    Net Income-$420.01M
    Reported EPS (TTM)-$4.49

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 89.34% of the $1.22B in total assets.

    Cash and Equivalents$261.45M
    Total Debt$0
    Net Cash$261.45M
    Net Cash Per Share$2.54
    Working Capital$775.56M
    Shareholder Equity$1.09B
    Book Value Per Share$10.61
    Total Assets$1.22B
    Total Liabilities$123.96M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $2.44M of capital spending, operating cash flow left -$349.80M of free cash flow.

    Operating Cash Flow-$347.36M
    Capital Expenditures$2.44M
    Free Cash Flow-$349.80M
    FCF Per Share-$3.63
    Depreciation and Amortization$5.89M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -1267.38%.

    Gross Margin100.00%
    Operating Margin-1267.38%
    Pretax Margin-1116.04%
    Net Margin-1149.62%
    FCF Margin-957.43%

    Growth

    Revenue grew 62.54% a year over 3 years.

    Revenue Growth (3Y CAGR)+62.54%
    Revenue Growth (5Y CAGR)+62.11%
    Book Value Per Share Growth (2Y CAGR)+10.14%
    Tangible Book Per Share Growth (2Y CAGR)+10.14%

    Revenue and profit by year

    Dividends and Yields

    IDYA does not pay a dividend. Its free cash flow yield is -12.40%.

    FCF Yield-12.40%
    Buyback Yield-12.68%
    Shareholder Yield-12.68%

    Peer Position

    Against 7 similar companies, IDYA has the 3rd highest P/S.

    P/S Ratio77.2x vs 13.1x median
    Revenue Growth (Trailing 4 Quarters, YoY)-82.99% vs -31.77% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -24.57% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-24.57%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About IDYA

    What is IDYA's market cap?

    Ideaya Biosciences has a market cap of $2.94B. Its enterprise value, which adds debt and subtracts cash, is $2.67B.

    How many shares of IDYA are outstanding?

    Ideaya Biosciences has 102.94M shares outstanding. The count is up 16.29% from a year earlier.

    Does IDYA pay a dividend?

    No. Ideaya Biosciences does not pay a dividend.

    How much debt does IDYA have?

    Ideaya Biosciences has $0 of total debt and $261.45M of cash and equivalents, a net cash position of $261.45M.